[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370411-105":59,"doc-detail-370411-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","observational-study-on-the-efficacy-and-safety-of-folfoxiri-therapy-for-locally-advanced-rectal-cancer-the-kanagawa-yokohama-colorectal-cancer-study-group-kycc1802","Observational study on the efficacy and safety of FOLFOXIRI therapy for locally advanced rectal cancer - The Kanagawa Yokohama Colorectal Cancer Study Group (KYCC)1802","","Purpose: Although chemoradiotherapy can treat locally advanced rectal cancer, radiological toxicities and late anal dysfunction remain major concerns. This study evaluated the efficacy and safety of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) as upfront therapy for marginally unresectable local rectal cancers without distant metastasis. Methods: A multicenter prospective observational design, with conversion rate as the primary endpoint. Results: Twenty patients were enrolled; the primary endpoint was achieved with an R0 resection rate of 80% (95% CI 56.3–94.3).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/observational-study-on-the-efficacy-and-safety-of-folfoxiri-therapy-for-locally-advanced-rectal-cancer-the-kanagawa-yokohama-colorectal-cancer-study-group-kycc1802/370411/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/observational-study-on-the-efficacy-and-safety-of-folfoxiri-therapy-for-locally-advanced-rectal-cancer-the-kanagawa-yokohama-colorectal-cancer-study-group-kycc1802/370411.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment strategy was evaluated in this observational study?","Question",{"text":112,"@type":113},"The study evaluated FOLFOXIRI as upfront therapy using folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan for marginally unresectable locally advanced rectal cancer without distant metastasis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the primary endpoint and what was the key outcome?",{"text":117,"@type":113},"The primary endpoint was the conversion rate. The study achieved the primary endpoint, with an R0 resection rate of 80% (95% CI 56.3 to 94.3).",{"name":119,"@type":110,"acceptedAnswer":120},"What adverse effects were commonly observed in major grade ≥ 3 events?",{"text":121,"@type":113},"Major grade ≥ 3 adverse effects included neutropenia (35%), anemia (15%), and fatigue (10%), along with enterocolitis (10%) and several other events each occurring in smaller proportions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370411,1790537547,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","International Journal of Colorectal Disease (2025) 40:82  \n[https://doi.org/10.1007/s00384-025-04873-2](https://doi.org/10.1007/s00384-025-04873-2)  \nObservational study on the efficacy and safety of FOLFOXIRI therapy for locally advanced rectal cancer: The Kanagawa Yokohama Colorectal Cancer Study Group (KYCC)1802  \nHironao Okamoto1 · Nobuhiro Sugano2 · Maho Sato1 · Kenta Iguchi1 · Masahiro Asari1 · Keisuke Kazama3 · Masakatsu Numata4 · Teni Godai5 · Akio Higuchi6 · Hiroyuki Mushiake7 · Aya Saito3 · Manabu Shiozawa1  \nAccepted: 23 March 2025 © The Author(s) 2025  \nAbstract  \nPurpose Although chemoradiotherapy is considered an efficacious treatment option for patients with locally advanced rectal cancer, the associated radiological toxicities and late anal dysfunction are concerning issues. Herein, we examined the efficacy and safety of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) as upfront therapy for marginally unresectable local rectal cancers without distant metastasis.  \nMethods This multicenter, prospective, observational study was designed by the Yokohama Colorectal Cancer Study Group. The primary endpoint was the conversion rate. Secondary endpoints were the R0 resection rate, response rate, pathological response rate, postoperative complication rate, relapse-free survival, local progression-free rate, and circumferential resection margin-negative rate.  \nResults Twenty patients were enrolled in this study. The study achieved its primary endpoint; the R0 resection rate was 80%(95% confidence interval, 56.3 to 94.3). Major grade ≥ 3 adverse effects included neutropenia in 7 (35%) patients, anemia in 3 (15%), fatigue in 2 (10%), enterocolitis in 2 (10%), febrile neutropenia in 1 (5%), leukopenia in 1 (5%), diarrhea in 1 (5%), fever in 1 (5%), and urinary tract infection in 1 (5%) .  \nConclusion FOLFOXIRI therapy was well tolerated and showed comparable efficacy results, providing potential R0 resection in patients with marginally unresectable locally advanced rectal cancer without distant metastasis.  \nTrial registration UMIN Clinical Trials Registry (UMIN000040275) .  \nKeywords FOLFOXIRI · Triplet · Rectal cancer · Chemoradiotherapy · Neutropenia  \n*  \n1  \n2  \n3  \n4  \nManabu Shiozawa  \n[shiozawa.0m702@kanagawa-pho.jp](shiozawa.0m702@kanagawa-pho.jp)  \nDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama City, Kanagawa 241-8515, Japan  \nDepartment of Surgery, Hiratsuka Kyousai Hospital, 9-11 Oiwake Hiratsuka-Shi, Kanagawa 254-0047, Japan  \nDepartment of Surgery, Yokohama City University, 3-9, Fukuura, Kanazawa-Ku, Yokohama City, Kanagawa 236-0004, Japan  \nGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-Cho Minami-Ku, Yokohama City, Kanagawa 232-0024, Japan  \n5 Department of Surgery, Fujisawa Shonandai Hospital, 2345 Takakura Fujisawa-Shi, Kanagawa 252-0802, Japan  \n6 Department of Gastrointestinal Surgery, Yokohama Minami Kyousai Hospital, 1-21-1 Mutsuurahigashi, Kanazawa-Ku, Yokohama City, Kanagawa 236-0037, Japan  \n7 Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, 3-2-10, Konandai, Konan-Ku, Yokohama City, Kanagawa 234-0054, Japan  \nIntroduction  \nThe standard surgical procedures for resectable rectal cancer include total mesorectal excision (TME) and tumorspecific mesorectal excision (TSME). The purpose of TMEis complete circumferential resection of the mesorectum, whereas TSME involves complete partial tumor-specific mesorectal resection. However, if TME or TSME procedures are the first choice of treatment for locally highly invasive advanced rectal cancer, the local recurrence rate will be high, owing to tumor exposure on the surgical resection surface, and surgical resection (R0) may be difficult [1] . Therefore, according to the ESMO and NCCN guidelines, chemoradiation should be performed before TME/TSME. One randomized phase III trial comparing preoperative chemoradiotherapy (CRT) and radiotherapy (","cbCaipEbu89JkO9L","https://ap.wps.com/l/cbCaipEbu89JkO9L","pdf",495466,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What treatment strategy was evaluated in this observational study?\",\"answer\":\"The study evaluated FOLFOXIRI as upfront therapy using folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan for marginally unresectable locally advanced rectal cancer without distant metastasis.\"},{\"question\":\"What was the primary endpoint and what was the key outcome?\",\"answer\":\"The primary endpoint was the conversion rate. The study achieved the primary endpoint, with an R0 resection rate of 80% (95% CI 56.3 to 94.3).\"},{\"question\":\"What adverse effects were commonly observed in major grade ≥ 3 events?\",\"answer\":\"Major grade ≥ 3 adverse effects included neutropenia (35%), anemia (15%), and fatigue (10%), along with enterocolitis (10%) and several other events each occurring in smaller proportions.\"}]","Observational study on the efficacy and safety of FOLFOXIRI therapy for locally advanced rectal cancer - The Kanagawa Yokohama Colorectal Cancer Study Group (KYCC)1802 | PDF",1790188385,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faa9431ad6180a76c8cda69b64dba40b.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8673f887de02dbb076aa6af1897c1db.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1964311d3e595236a690b145290e7129.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a67dc122938f0e2a728bf808224db6f2.webp",980,1301]